Prescribed to treat anxiety and insomnia, benzodiazepines may do more than put the mind at ease. A new study links their prolonged use to increased Alzheimer’s risk.
Expansions in ataxin 2 predispose people to the ALS end of the ALS-FTD spectrum, and never cause pure FTD, according to a new French study.
When strict quality control standards are followed, low Aβ in cerebrospinal fluid accurately predicts amyloid plaques in people with cognitive impairment in clinical practice.
A new drug combination is better than standard therapy for congestive heart failure. It includes an inhibitor of neprilysin, a protease that digests Aβ in the brain.
Researchers in the United States, France, and Austria honored for pioneering work on deep-brain stimulation and L-dopa.
Moving beyond cell culture, neuroscientists are using CRISPR to tweak genes in living animals and perhaps, one day, as therapy in humans.
A hot new tool, CRISPR empowers researchers to slice, dice, and add their own spice to any gene. Neuroscientists are starting to reap the benefits.
The ALS Ice Bucket Challenge has yielded more than $100 million—what research projects should get a share of the action?
Five papers detail the latest on how gene expression is controlled in people, worms, and flies.
A new database will help scientists trace genetic variants to the genes that truly affect a person’s risk of disease.
Transcranial magnetic stimulation of the parietal cortex strengthens a hippocampal network involved in associative memory and transiently improves memory performance.
Improved magnetic resonance imaging methods confirm damage in a subclass of motor neurons in ALS.
In a reverse twist on the spread of pathology in Alzheimer’s, axonal proteins translated in the presence of Aβ migrate back to cell bodies, where they promote cell death.
Aβ in mitochondria slows the maturation of proteins that enter the organelle from cytosol, according to a new study. The finding could help explain the wide range of mitochondrial deficits seen in Alzheimer’s disease.